PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.

Abstract Trastuzumab® is used for human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. Our aim was to compare HER2 expression by immunohistochemistry (IHC) and dual in situ hybridization (DISH) in early-stage vs. late-stage gastric and GEJ tumors.
PMID
Related Publications

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.

Authors

Mayor MeshTerms
Keywords

DISH

HER2

esophageal cancer

gastric cancer

Journal Title anticancer research
Publication Year Start




PMID- 29277796
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in
      Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
PG  - 367-372
AB  - BACKGROUND/AIM: Trastuzumab(R) is used for human epidermal growth factor receptor
      2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ)
      adenocarcinoma. Our aim was to compare HER2 expression by immunohistochemistry
      (IHC) and dual in situ hybridization (DISH) in early-stage vs. late-stage gastric
      and GEJ tumors. MATERIALS AND METHODS: Fifty early-stage and 50 late-stage
      gastric tumors and a similar number of early-stage and late-stage GEJ tumors were
      studied. HER2 was analyzed by IHC and dual-ISH using tissue microarray. RESULTS: 
      Of 200 selected cases, 168 had satisfactory results. Among the 110 cases with
      both tests successfully performed, there were only five cases with discrepancy
      between assays (4.5%). Seven equivocal (2+) cases by IHC were all found to be
      amplified by dual-ISH. When compared with IHC, dual-ISH identified 12 additional 
      HER2-positive cases (10.9%). CONCLUSION: The 12.5% overall
      overexpression/amplification in gastric and GEJ adenocarcinomas is in concordance
      with previous reports. No correlation was found between tumor stage and HER2
      overexpression/amplification. Determination of HER2 in limited tissue samples
      benefits from combinational IHC and ISH testing.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Dominguez, Carolina
AU  - Dominguez C
AD  - Department of Pathology and Laboratory Medicine, University of South Florida,
      Tampa, FL, U.S.A.
FAU - Rosa, Marilin
AU  - Rosa M
AD  - Department of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research
      Institute, Tampa, FL, U.S.A.
FAU - George, Taara B
AU  - George TB
AD  - Department of Arts and Science, University of South Florida, Tampa, FL, U.S.A.
FAU - Pimiento, Jose
AU  - Pimiento J
AD  - Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research 
      Institute, Tampa, FL, U.S.A.
FAU - Lauwers, Gregory Y
AU  - Lauwers GY
AD  - Department of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research
      Institute, Tampa, FL, U.S.A.
FAU - Coppola, Domenico
AU  - Coppola D
AD  - Department of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research
      Institute, Tampa, FL, U.S.A. [email protected]
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/drug therapy/*pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Biomarkers, Tumor/*metabolism
MH  - Esophageal Neoplasms/drug therapy/*pathology
MH  - Esophagogastric Junction/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Retrospective Studies
MH  - Stomach Neoplasms/drug therapy/*pathology
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - *DISH
OT  - *HER2
OT  - *esophageal cancer
OT  - *gastric cancer
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2017/11/13 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/367 [pii]
AID - 10.21873/anticanres.12231 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):367-372. doi: 10.21873/anticanres.12231.